Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acid

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 4, 2008, Pages 322-324

  Niego, Be'eri ^a   Horvath, Anita ^a   Coughlin, Paul B ^a   Pugsley, Michael K ^b   Medcalf, Robert L ^a  

^a MONASH UNIVERSITY   (Australia)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DESMOTEPLASE; FIBRIN; PLASMINOGEN; TRANEXAMIC ACID;

BLOOD CLOT LYSIS; CONCENTRATION RESPONSE; DRUG ANTAGONISM; FIBRINOLYSIS; HUMAN; LETTER; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

ANTIFIBRINOLYTIC AGENTS; DRUG INTERACTIONS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PLASMINOGEN; PLASMINOGEN ACTIVATORS; TRANEXAMIC ACID;

EID: 43449091610     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282f54568     Document Type: Letter

References (9)

1. Royston D. Blood-sparing drugs: aprotinin, tranexamic acid, and epsilonaminocaproic acid. Int Anesthesiol Clin 1995; 33:155-179.
2. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57:1005-1032.
3. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989; 111:1010-1022.
4. Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980; 14:41-47.
5. Andersson L, Nilsoon IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci 1968; 146:642-658.
6. Bringmann P, Gruber D, Liese A, Toschi L, Kratzchmar J, Schleuning WD, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270:25596-25603.
7. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-h window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66-73.
8. Verheijen JH, Caspers MP, Chang GT, de Munk GA, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5:3525-3530.
9. Renatus M, Stubbs MT, Huber R, Bringmann P, Donner P, Schleuning WD, Bode W. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. Biochemistry 1997; 36:13483-13493.